SIGNIFICANCE OF CA15-3 IN CARCINOMA OF THE BREAST WITH VISCERAL METASTASES
DOI:
https://doi.org/10.55519/JAMC-S4-7329Abstract
Background: The most common malignancy and second most common cause of death is breast cancer among women. About 2.09 million fatalities from breast cancer happened in 2018. The objective was to evaluate the elevated CA15-3 in breast cancer patients with visceral metastases presenting at the tertiary care hospital of Karachi. Methods: It was a cross-sectional study conducted at the Department of Oncology of Jinnah Postgraduate Medical Center from 15th December 2018 to 15th November 2019. Female patients aged 26–80 years diagnosed with visceral metastatic (defined as metastasis to lung, liver, brain and adrenal glands) breast cancer were included in the study. The diagnosis of breast cancer was confirmed on histopathology whereas the metastatic sites were evaluated using physical examination and imaging. The serum CA15-3 concentration was assessed using assay kits. The serum CA15-3 level of 0-32 U/ml was taken as normal range for all the patients whereas CA15-3 level greater than 32 U/L was considered as elevated CA15-3. SPSS version 23 was used to enter and analyze data. Results: A total of 139 females were included in the study. The mean age & BMI of the patients were reported as 46.5 years & 26.69 kg/m2. In the majority of the patients’ metastases were detected in the liver (n=54), 92 in the lungs+ parenchymal disease, 20 in adrenal glands, 12 in pleural effusion and 10 in the brain. Out of 139 patients with visceral metastases, 52(37.4%) had normal CA15-3 level whereas 87 (62.6%) had elevated serum CA15-3 levels (>32 U/L). Conclusion: The serum CA15-3 tumour marker is elevated significantly in visceral metastases and can be used as a prognostic marker in metastatic breast cancer patients.References
REFERENCES
WHO. Cancer, Key facts: World health organization; 2018 [cited 2019 2-Jul]. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer.
Breastcancer.org. U.S. Breast Cancer Statistics 2019 [cited 2 Jul 2019]. Available from: https://www.breastcancer.org/symptoms/understand_bc/statistics.
Asif HM, Sultana S, Akhtar N, Rehman JU, Rehman RU. Prevalence, risk factors and disease knowledge of breast cancer in Pakistan. Asian Pac J Cancer Prev. 2014;15(11):4411-6.
Cancer.net. Breast Cancer: Statistics: American Society of Clinical Oncology (ASCO); 2019 [cited 2019 3 Jul]. Available from: https://www.cancer.net/cancer-types/breast-cancer/statistics.
Breastcancer.org. 2017 Breast Cancer Statistics Show Survival Rates Improving 2017 [cited 2019 11 Jul]. Available from: https://www.breastcancer.org/research-news/2017-stats-show-survival-rates-improving.
Harb WA. Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment options. Cancer Manag Res. 2015;7:37-46.
Yardley DA. Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents. Clin Breast Cancer. 2010;10(1):64-73.
Imamura M, Morimoto T, Nomura T, Michishita S, Nishimukai A, Higuchi T, et al. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes. World J Surg Oncol. 2018;16(1):26.
Bahrami-Ahmadi A, Makarian F, Mortazavizadeh MR, Yazdi MF, Chamani M. Symptomatic metastasis prediction with serial measurements of CA 15.3 in primary breast cancer patients. J Res Med Sci. 2012;17(9):850-4.
Dong Y, Hou H, Wang C, Li J, Yao Q, Amer S, et al. The Diagnostic Value of 18F-FDG PET/CT in Association with Serum Tumor Marker Assays in Breast Cancer Recurrence and Metastasis. BioMed Research International. 2015;2015:5.
Laessig D, Nagel D, Heinemann V, Untch M, Kahlert S, Bauerfeind I, et al. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients. Anticancer Res. 2007;27(4a):1963-8.
Cronin-Fenton D, Kjaersgaard A, Norgaard M, Amelio J, Liede A, Hernandez RK, et al. Breast cancer recurrence, bone metastases, and visceral metastases in women with stage II and III breast cancer in Denmark. Breast Cancer Res Treat. 2018;167(2):517-28.
Fejzic H, Mujagic S, Azabagic S, Burina M. Tumor marker CA 15-3 in breast cancer patients. Acta Med Acad. 2015;44(1):39-46.
Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and Mortality and Epidemiology of Breast Cancer in the World. Asian Pac J Cancer Prev. 2016;17(S3):43-6.
Berruti A, Tampellini M, Torta M, Buniva T, Gorzegno G, Dogliotti L. Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer. 1994;30a(14):2082-4.
Taghizadeh A, Pourali L, Joudi M, Salehi M, Eshghi S, Torabian F, et al. Assessment of Elevated Serum Tumor Markers Carcinoembryonic Antigen (CEA) and Cancer Antigen 15-3 (CA15-3) among Patients with Different Subtypes of Metastatic Breast Cancer. Middle East Journal of Cancer. 2019;10(1):17-22.
Ali HQ, Mahdi NK, Al-Jowher MH. The value of CA15-3 in diagnosis, prognosis and treatment response in women with breast cancer. J Pak Med Assoc. 2013;63(9):1138-41.
Nieder C, Dalhaug A, Haukland E, Mannsaker B, Pawinski A. Prognostic Impact of the Tumor Marker CA 15-3 in Patients With Breast Cancer and Bone Metastases Treated With Palliative Radiotherapy. J Clin Med Res. 2017;9(3):183-7.
Fatima H, Maqbool A, Siddiqui M, Haider G, Sohail H, Saleem O, et al. Significance of Tumor Marker CA15-3 in Metastatic Breast Cancer. Journal of Cancer and Tumor International. 2016:1-12.
Shao Y, Sun X, He Y, Liu C, Liu H. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer. PLoS One. 2015;10(7):e0133830.
Osman AM, Hamid ME, Satti AH, Goreish IA. High Concentration of Tumor Marker Cancer Antigen CA15-3 in Breast CancerPatients after Surgery. Breast Can Curr Res. 2016;1(4).
Darlix A, Lamy PJ, Lopez-Crapez E, Braccini AL, Firmin N, Romieu G, et al. Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients. BMC Cancer. 2016;16:428.
Hosseini S. M, Razmjoo S, Arvandi S. H, Barat T. CEA and CA 15-3 Serum Level in Metastatic Breast Cancer and its Correlation with Distant Metastasis. Biomed Pharmacol J 2015;8(October Spl Edition).
Additional Files
Published
Issue
Section
License
Copyright (c) 2024 Journal of Ayub Medical College Abbottabad
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
